B-hDLL3 B16-F10_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

한국

미국

일본

중국

영국

호주

프랑스

독일

이탈리아

싱가포르

인도

러시아

캐나다

스위스

기타 국가

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

B-hDLL3 B16-F10

Common name	B-hDLL3 B16-F10	Catalog number	321826
Aliases	DLL3, SCDO1, delta like canonical Notch ligand 3	Disease	Melanoma
Organism	Mouse	Strain	C57BL/6
Tissue types	Skin	Tissue	Skin

Description

The mouse Dll3 gene was replaced by chimeric human DLL3 coding sequence in B-hDLL3 B16-F10 cells. Human DLL3 is highly expressed on the surface of B-hDLL3 B16-F10 cells.

Application

B-hDLL3 B16-F10 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeted allele

Gene targeting strategy for B-hDLL3 B16-F10 cells. The exogenous promoter and chimeric human DLL3 coding sequence was inserted to replace part of murine exon 2 and all of exons 3-5. The insertion disrupts the endogenous murine Dll3 gene, resulting in a non-functional transcript.

Protein expression analysis

from clipboard

DLL3 expression analysis in B-hDLL3 B16-F10 cells by flow cytometry. Single cell suspensions from wild-type B16-F10 and B-hDLL3 B16-F10 cultures were stained with anti-DLL3 antibody. The mouse antibody is cross-reactive between human and mouse. Human DLL3 was detected on the surface of B-hDLL3 B16-F10 cells but not wild-type B16-F10 cells. The 1-E07 clone of B-hDLL3 B16-F10 cells was used for in vivo tumor growth assays.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hDLL3 B16-F10 cells. B-hDLL3 B16-F10 cells (2x10⁵) and wild-type B16-F10 cells (2x10⁵) were subcutaneously implanted into C57BL/6 mice (female, 7-week-old, n=8). Tumor volume and body weight were measured three times a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean ± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hDLL3 B16-F10 cells were able to form tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

from clipboard

B-hDLL3 B16-F10 cells were subcutaneously transplanted into C57BL/6 mice (n=8), and on 18 days post inoculation, tumor cells were harvested and assessed for human DLL3 expression by flow cytometry using anti-mouse DLL3 antibody that is cross-reactive between human and mouse. As shown, human DLL3 was highly expressed on the surface of tumor cells. Therefore, B-hDLL3 B16-F10 cells can be used for in vivo efficacy studies of DLL3 therapeutics.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hDLL3 B16-F10 cells. B-hDLL3 B16-F10 cells (2x10⁵) and wild-type B16-F10 cells (2x10⁵) were subcutaneously implanted into B-hCD3E/hCD28 mice (female, 7-week-old, n=5). Tumor volume and body weight were measured three times a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean ± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hDLL3 B16-F10 cells were able to form tumors in vivo and can be used for efficacy studies.